Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1-year randomized double-blind placebo-controlled Phase 3 study of CP-945,598 in overweight subjects with type 2 diabetes mellitus
2006-005192-18Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and type 2 diabetes mellitus (T2DM) comparing CP-945,598 with Placebo (2 arms). Primary endpoint: Percent change in body weight from baseline to 1 year. Started Dec 2006; status: terminated.
02
Drugs
otenabant
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-005192-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005192-18.